Citations

Clear

4610 citation(s) found for "Lu, Brian".

MRI Analysis of Cardiac Fat, Abdominal Adiposity and Cardiac Function After Vertical Sleeve Gastrectomy in Youth With Type 2 Diabetes
Dobbs, Tyler , Gutierrez, Linnea, Hunter, Kendall S. , Fonseca, Brian, Browne, Lorna P. , Winter, D. , Cree‐Green, Melanie , Pyle, Laura , Hills‐Dunlap, Jonathan L. , Reusch, Jane E.B. , Dobbs, Tyler J , Hu, Houchun Harry , Inge, Thomas H , Gutierrez, Linnea, Hu, Peng , Winter, David, Kelsey, Megan Moriarty , Inge, Thomas H. , Bjornstad, Petter , Nadeau, Kristen J

Mayo Clinic

Pediatric Obesity | November 18, 2025 | Volume: 21 | Issue: 1 | Pages: No page available

10.1111/ijpo.70068 | PMID 41251158 Get It

ABSTRACT Background Adolescents with youth‐onset type 2 diabetes (YO‐T2D) have an increased risk for cardiometabolic complications. The impact of vertical sleeve gastrectomy (VSG) on fat distribution and cardiac morphology/function in YO‐T2D is unknown. Objectives To evaluate changes in body composition, abdominal and cardiac fat depots, and cardiometabolic health in adolescents with YO‐T2D undergoing VSG. Methods Anthropometrics, labs and imaging were used to assess participants pre‐surgery and 3–12 months post‐surgery. MRI quantified pericardial (PAT), epicardial (EAT), subcutaneous (SAT) and visceral adipose tissue (VAT), hepatic fat fraction (HFF) and cardiac morphology/function. Mixed‐effects models assessed longitudinal changes. Results By 12 months, weight decreased from 134.3 ± 5.1 to 103.3 ± 5.2 kg, VAT 1943 ± 148 to 1248 ± 150 cm 3 , HFF 23.2% ± 2.3% to 5.3% ± 2.3% and PAT and EAT by 27% and 33% (all p < 0.01). Homeostatic model assessment of insulin resistance (HOMA‐IR) improved (7.8 ± 1.2 to 1.7 ± 1.2 [ p < 0.01]). BMI, SAT, resting heart rate (RHR), left ventricular (LV) mass and cardiac output (CO) also decreased (all p < 0.05). VAT decreases correlated with decreases in HFF ( r = 0.70, p = 0.01), HOMA‐IR ( r = 0.60, p = 0.04) and CO ( r = 0.70, p = 0.03). HFF decreases correlated with decreases in BMI ( r = 0.70, p = 0.03), HOMA‐IR ( r = 0.90, p < 0.001), RHR ( r = 0.90, p = 0.002), CO ( r = 0.80, p = 0.007) and LV mass ( r = 0.70, p = 0.02). Conclusions VSG reduces ectopic and regional fat and improves associated insulin sensitivity and cardiac health in adolescents with YO‐T2D.
Highly Coordinated Cochlear Implant Care With Remote Programming: Clinical, Financial, and Implementation Outcomes for the Complete Cochlear Implant Care (CCIC) Model
Nassiri, Ashley M. , Saoji, Aniket A. , DeJong, Melissa D., Tombers, Nicole M. , Lohse, Christine M. , Driscoll, Colin L. W., Neff, Brian A., Haynes, David S. , Daher, Ghazal S. , Carlson, Matthew L., Moriarty, James P. , Borah, Bijan J. , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | November 14, 2025 | Volume: 47 | Issue: 2 | Pages: e201-e207

10.1097/mao.0000000000004720 | PMID 41236091 Get It

Objective: The Complete Cochlear Implant Care (CCIC) model is a highly coordinated care delivery model reducing and condensing in-person visits for cochlear implant (CI) patients, leveraging telehealth and remote programming. Clinical, quality-of-life, implementation, patient experience, and financial outcomes of the clinical trial are reported. Study design: Prospective, nonrandomized, 2-arm clinical trial Setting: Tertiary referral CI center Patients: Adult CI candidates Interventions: Cochlear implantation Main outcome measures: Speech perception, quality of life, implementation, patient experience, and financial outcomes for both CCIC and traditional care delivery models. Results: Patients participating in the traditional and CCIC delivery models demonstrated 12-month postoperative speech perception scores comparable to nationally reported outcomes (CNC 61% and 72% and AzBio in quiet 75% and 87% for traditional and CCIC cohorts, respectively). Quality-of-life evaluation using the CIQOL-10 demonstrated similar 12-month postoperative scores between groups (52 and 54 for traditional and CCIC cohorts, respectively). The CI Patient Experience Survey demonstrated high satisfaction outcomes in ease of communication, preparedness for surgery, and overall care in both cohorts. Implementation analysis of the CCIC model revealed perceived benefits from staff and clinicians; however, support for expansion of the program was contingent upon the availability of app-based or web-based remote programming technology. Finally, financial analysis revealed decreased out-of-pocket costs for CCIC patients. Conclusion: The CCIC model has the potential to dramatically streamline hearing health care delivery and reduce out-of-pocket costs for CI recipients. Clinical outcomes between cohorts were comparable in this feasibility study; however, a sufficiently powered trial is required to definitively comment on clinical outcomes with the new care delivery model.
International Reference Values for Surgical Outcomes of Total Pancreatectomy
Berchtold, Caroline , Kuemmerli, Christoph, Li, Zhihao , Eden, Janina , Wu, Pengfei , Cecchetto, Sara Nicole, Kendrick, Michael L. , Pecorelli, Nicolò , Guarneri, Giovanni , Farooqui, Waqas , Tschuor, Christoph , Burgdorf, Stefan Kobbelgaard , Mühlhäusser, Julia , Gass, Jörn‐Markus , Koh, Ye-Xin, Seip, Tomas, Santibañes, Martín de , Todeschini, Letizia , Marchegiani, Giovanni, Belfil, Nadiya , Boggi, Ugo, Cappelle, Marie , Koerkamp, Bas Groot , Dutkowski, Philipp , Hackert, Thilo , Truty, Mark J. , Group, Outcomes for Total Pancreatectomy, Valle, Valentina , Giulianotti, Pier Cristoforo , Pessaux, Patrick, Thapa, Prabin , Kuzman, Matta , Pandanaboyana, Sanjay, He, Jin , Kendrick, Michael, Truty, Mark, Li, Zhihao , Groot Koerkamp, Bas , Müller, Philip C , Breuer, Eva , Vallorani, Alessia , Hansen, Carsten Palnæs , Guidetti, Cristiano , Campbell, Brady A. , Cecchetto, Sara Nicole, Gudmundsdottir, Hallbera , Starlinger, Patrick , Goh, Brian K P , Koh, Ye-Xin , Rebelo, Artur , Kleeff, Jorg H. , Marchegiani, Giovanni , Lesurtel, Mickaël , Machado, Marcel Autran C. , Kauffmann, Emanuele F. , Benedetto, Fabrizio Di , Roberts, Keith John , Nevler, Avinoam , Lavu, Harish , Nickel, Felix , He, Jing , Falconi, Massimo , Billeter, Adrian T. , Müller-Stich, Beat Peter , Group, Outcomes for Total Pancreatectomy, Halle-Smith, James Michael , Giannone, Fabio , Pessaux, Patrick , Sánchez‐Velázquez, Patricia , Maharjan, Dhiresh Kumar , Torres, Orlando Jorge Martins

Mayo Clinic

JAMA Surgery | November 12, 2025 | Volume: 161 | Issue: 1 | Pages: 50

10.1001/jamasurg.2025.4941 | PMID 41222926 Get It

Importance Total pancreatectomy (TP) is indicated for advanced pancreatic cancer or multifocal tumors. Furthermore, TP may be performed to avoid the risk of pancreatic fistula in selected patients to improve the perioperative risk profile. Objective To define reference values for TP based on a low-risk cohort treated at expert centers. Design, Setting, and Participants This multicenter study analyzed outcomes from patients undergoing primary TP for malignant or benign lesions from 25 international expert centers from January 2017 to November 2023. Low-risk patients undergoing TP (LR-TP) were without vascular resections or significant comorbidities. Exposures TP. Main Outcomes and Measures Twenty reference values were derived from the 75th or the 25th percentile of the median values of all centers. Outcomes of LR-TP were compared with a cohort of TP with vascular resection, TP due to high-risk pancreatic anastomosis, and the benchmark values for low-risk pancreatoduodenectomy. Results Of 994 patients, 333 (33.5%; median [IQR] age, 66 [58-72] years; 171 male [51.4%]) qualified as the LR-TP cohort. Reference values included blood loss (≤1000 mL), major complications (≤37%), 3-month postoperative mortality (&amp;lt;6%), and retrieved lymph nodes (≥29). Compared with TP with vascular resections, reference cutoffs were not met for major complications (51% vs LR-TP ≤37%) and 90-day mortality (11% vs LR-TP ≤6%). For TP due to high-risk anastomosis, failure to rescue rate (38% vs ≤6%) and 90-day mortality (11% vs LR-TP ≤6%) were not met. Compared with pancreatoduodenectomy, reference values for postoperative mortality were 3 times higher for LR-TP (≤2% vs ≤6%) and less for resected lymph nodes (≥16 vs ≥29). Conclusions and Relevance This case-control study provided global reference values for TP, indicating significantly higher postoperative morbidity and mortality compared with pancreatoduodenectomy. Perioperative morbidity of TP was especially increased in patients with vascular resections. These reference values can serve for quality control of pancreatic surgery.
Meniscal Repair in the Setting of Revision Anterior Cruciate Ligament Reconstruction: 6-Year Follow-up Results From the MARS Cohort
Group;, MARS, Fox, Jake A. , Huston, Laura J. , Haas, Amanda K. , Cooper, Daniel E. , Dunn, Warren R. , Lantz, Brett A., Amendola, Annunziato , Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Bush‐Joseph, Charles A., Butler, J. Brad, Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cooper, Jonathan M. , Creighton, R. Alexander , Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Gatt, Charles J. , Gecha, Steven R., Hame, Sharon L. , Hannafin, Jo A., Harner, Christopher D. , Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Johnson, David C. , Kaeding, Christopher C., Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, C. , Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McCormack, Robert G. , Miller, Bruce S., Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Shea, Kevin G. , Slauterbeck, James R., Smith, Matthew V. , Svoboda, Col. Steven J., Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Williams, James S., Wolcott, Michelle L., York, James J. , Wright, Rick W. , Svoboda, Steven J. , Group;, MARS, Pennings, Jacquelyn S. , Allen, Christina R. , DeBerardino, Thomas M. , Spindler, Kurt P , Stuart, Michael J., Brophy, Robert H. , Carpenter, James E., Cox, Charles L. , David, Tal S. , Flanigan, David C. , Giffin, J. Robert , Johnson, David C., Johnson, Timothy S. , Jones, Morgan H. , Kaeding, Christopher C. , Marx, Robert G. , McAllister, David R. , McCarty, Eric C. , Miller, Bruce S., Owens, Brett D. , Sherman, Orrin H. , Spang, Jeffrey T. , Vidal, Armando F. , Wolf, Brian R.

Mayo Clinic

The American Journal of Sports Medicine | November 12, 2025 | Volume: 53 | Issue: 14 | Pages: 3435-3445

10.1177/03635465251387333 | PMID 41220248 Get It

Background: Meniscal preservation has been demonstrated to contribute to long-term knee health and has been a successful intervention in isolation and in patients with anterior cruciate ligament reconstruction (ACLR). The long-term results of meniscal repair in the setting of revision ACLR have yet to be documented. Purpose: To report the incidence of meniscal repair failures at the 6-year follow-up in a cohort of patients who underwent concurrent revision ACLR and primary meniscal repair. Study Design: Prospective cohort study; Level of evidence, 2. Methods: All revision ACLRs with concomitant primary meniscal repair cases from a multicenter group between 2006 and 2011 were selected. Six-year follow-up was obtained to determine whether any subsequent surgery had occurred since their initial revision ACLR. If so, operative reports were obtained, whenever possible, to verify pathological condition and treatment. Results: In total, 221 patients from 1234 revision ACLRs underwent concurrent primary meniscal repairs (18% of the cohort). There were 238 repairs performed: 173 medial and 65 lateral. The majority of these repairs (n = 181; 76%) were performed with an all-inside technique. Six-year surgical follow-up was obtained in 77% (171/221) of the cohort, or 189 of 238 (79%) of the repairs (136 medial, 53 lateral). The meniscal repair failure rate, defined as reoperation, was 16% (31/189) at 6 years. Of the 31 failures, 28 were medial (24 all-inside, 4 inside-out; 28/136 = 20.6% failure rate) and 3 were lateral (2 all-inside, 1 inside-out; 3/53 = 5.7% failure rate). Three medial failures were treated in conjunction with a subsequent repeat revision ACLR. Medial tears underwent reoperation for failure at a significantly higher rate than lateral tears (20.6% vs 5.7%; P = .01) and had a significantly shorter survival time compared with lateral tears ( P = .02). No difference was found between the failure and nonfailure groups when it came to tear type, tear length, repair technique utilized, suture/implant type, or number of sutures used between the 2 groups. Conclusion: Meniscal repair in the revision ACLR setting has a 16% failure rate at 6 years. Failure rates for medial tears (20.6%) were found to be higher than that for lateral tears (5.7%), which aligns with previous studies in both the revision and primary ACLR setting.
Systemic mRNA vaccines elicit rapid immune activation in canine brain tumors
Aghaee, Mahya , Qdaisat, Sadeem, Weidert, Frances, Garcia, Gabriel , Fagman, Lana, Stover, Brian, Moor, Rachel S F, Goldenberg, Eden, Chardon‐Robles, Jonathan, Elliott, Leighton , Foster, Timothy P. , Rahman, Maryam, Ghiaseddin, Ashley , Castillo, Paul , Lee, Ji‐Hyun , Doty, Andria , Milner, Rowan J. , Mitchell, Duane A. , Méndez-Gómez, Héctor , Carrera-Justiz, Sheila , Aghaee, Mahya , Doonan, Bently , Deleyrolle, Loic P. , Ligon, John A , Milner, Rowan J , Moore, Helen , Sayour, Elias J , Zhang, Dingpeng , Moor, Rachel S F, Xie, Chao Lian , Goldenberg, Eden, Roemeling, Christina A. Von , Doonan, Bently P. , Sawyer, W. Gregory , Sahay, Bikash , Seligson, Nathan D. , Silver, Natalie L.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | November 11, 2025 | Volume: 13 | Issue: 11 | Pages: e011817

10.1136/jitc-2025-011817 | PMID 41218853 Get It

Malignant glioma is considered invariably recalcitrant, thus necessitating development of new therapeutic approaches. Spontaneously arising canine glioma exhibits important molecular and pathological similarities to malignant pediatric glioma, making it an invaluable model for testing novel therapies. We evaluated safety and activity of RNA lipid particle aggregates (LPAs) designed to provoke cancer immunogenicity in 10 dogs with histologically confirmed glioma. Vaccine manufacturing was feasible in all subjects and generally well tolerated. Median survival time was 123 and 155 days in dogs receiving three (Group A) or four (Group B) vaccines, respectively; this was increased from historical reporting of subjects receiving palliative care. Responding animals had a robust cytokine response following infusions. In animals receiving non-specific RNA-LPAs, there was localization of messenger RNA (mRNA) payloads to the brain tumor microenvironment and a rapid shift in immunologic gene signatures consistent with a viral response. These data demonstrate the ability to induce rapid viremic response in the tumor microenvironment following a single peripherally administered mRNA vaccine. Since RNA-LPAs are amenable to repeat boosts, these formulations may overcome challenges of tumor immunosuppression and therapeutic access and are currently under evaluation in first-in-human trials ( NCT04573140 , NCT06389591 ).
Quality of life and healthcare resource utilization among adult patients with short bowel syndrome: A mixed‐methods study leveraging an integrated database
Kuk, Deborah , Gower, Megan, Kirby, Michelle, Terreri, Brian , Feldman, Josh , Mundi, Manpreet S. , Feldman, Josh , Mundi, Manpreet S , Chen, Brian , McCue, Maggie

Mayo Clinic

Nutrition in Clinical Practice | November 11, 2025 | Volume: 41 | Issue: 4 | Pages: 1096-1105

10.1002/ncp.70059 | PMID 41215658 Get It

Abstract Background Short bowel syndrome (SBS) is a chronic condition requiring parenteral nutrition (PN) support and multidisciplinary management. However, disparities in access to care and standardized treatment pathways, in addition to economic burden, remain considerable for patients. Understanding healthcare resource utilization (HCRU) and treatment patterns, especially in relation to patient‐reported outcomes (PROs), is critical for improving care. Methods A cross‐sectional, multiphase study was conducted in 2023. This analysis focuses on phase 3, using a deidentified database that integrated claims and PROs from 68 patients in phase 2. Twenty‐three patients were included in the analytic cohort after applying additional criteria. Descriptive statistics summarized patient demographics, HCRU, and treatment patterns for the overall cohort and stratified by median SBS–quality of life (QoL) score. Results The median age at SBS diagnosis was 35 years, and 91% of patients were female. Patients saw a median of 35 different healthcare providers and underwent approximately five procedures before diagnosis. In the 6 months after diagnosis, 39% had been hospitalized, and 26% had emergency room (ER) visits. Healthcare costs increased after diagnosis, with long‐term PN use accounting for 34% of total costs. Patients with worse QoL had a higher number of ER visits than patients with better QoL. Patients who self‐reported being treated by SBS specialists had lower healthcare costs than patients who did not receive specialized care. Conclusion SBS is associated with high HCRU and costs, particularly for patients with poor QoL. Multidisciplinary care, especially from SBS specialists, may help reduce healthcare costs and improve patient outcomes.
CTNI-30. ALLIANCE A071601: PHASE II TRIAL OF BRAF/MEK INHIBITION IN RECURRENT PAPILLARY CRANIOPHARYNGIOMAS
Geyer, Susan, Kabat, Brian, Gerstner, Elizabeth R. , Choi, Yoon Jae, Fuente, Macarena I. de la , Lesser, Glenn J. , Kumthekar, Priya , Vora, Shivangi, Knopp, Michael V. , Iafrate, A. John , Brown, Paul D. , Barker, Frederick G., Brastianos, Priscilla K. , Reed, Sarah, Kaufmann, Timothy J. , Barbaro, Marissa , Cahill, Daniel P. , Shih, Helen A. , Santagata, Sandro , Galanis, Evanthia

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v132-v133

10.1093/neuonc/noaf201.0527 Get It

Abstract BACKGROUND Craniopharyngiomas are a rare tumor along the pituitary-hypothalamic axis. Genetic analysis revealed that 95% of papillary craniopharyngiomas (PCP) have BRAF V600E mutations (Brastianos et al. Nature Genetics 2014). We previously reported that BRAF/MEK inhibition was associated with significant anti-tumor activity in newly-diagnosed PCP patients (Brastianos et al. NEJM 2023). We have now evaluated the efficacy of vemurafenib/cobimetinib in a separate cohort of patients with recurrent PCP whose tumors progressed after prior radiation. METHODS In this multicenter, NCI-sponsored cooperative group trial, patients with histologically confirmed BRAF-positive PCP who progressed after radiation were treated with vemurafenib/cobimetinib. The primary endpoint of response rate (RR) based on centrally determined imaging data was to be evaluated in 16 patients, where a partial response was defined as ≥20% decrease in volume. This single arm, Simon two-stage phase 2 trial had 89% power to detect a true RR ≥ 30% (vs. null 5%; α=0.04). In this design, 3 or more observed responses in 16 evaluable patients would be considered evidence of promising activity. RESULTS Of the planned 16 patients, a total of 5 patients enrolled before the study was closed due to slow accrual. Median follow-up was 50 months (95% CI: 32 to not yet reached). Based on volumetric response criteria, all 5 patients had a response to treatment (100%; 95% CI: 47.8% to 100%). To date, 2 patients progressed, one of whom died 22 months after study entry. This cohort met the criteria for efficacy under the original design with &gt;3 responders. No grade 4 or 5 toxicities were observed. CONCLUSIONS Vemurafenib/cobimetinib resulted in an objective response in all patients with previously treated PCP. The study met primary endpoint, similar to that reported for previously untreated PCP. Thus, BRAF/MEK inhibitors could be an effective tool for previously treated PCP and warrants further evaluation. SUPPORT U10CA180821; U10CA180882; Genentech, https://acknowledgments.alliancefound.org;ClinicalTrials.gov: NCT03224767
EPCO-47. DISSECTING MYC-DRIVEN EPIGENETIC MECHANISMS THAT PROMOTE GROUP 3 MEDULLOBLASTOMA UTILIZING HUMANIZED IPSC MODELS
Qadeer, Zulekha A. , Hou, Elise, Siegel, Dara, Westelman, Samantha, Gudenas, Brian , Smith, Kyle , Wang, Linyu , Beytagh, Mary C. , Phua, Ronald, Taylor, Michael D. , Ismail, Wazim Mohammed , Wang, Linyu, Hendrikse, Liam D. , Huang, Miller , Gaspar‐Maia, Alexandre , Northcott, Paul A , Taylor, Michael D. , Weiss, William A.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v13-v13

10.1093/neuonc/noaf201.0046 Get It

Abstract Medulloblastoma (MB) is one of the most prevalent malignant brain tumors in children, with tremendous cognitive and neuroendocrine disability among survivors. Group 3 (G3) MBs have poor overall survival at &lt;50%, higher frequency of metastasis, and no targeted therapies. Amplification of MYC and activation of TGFβ signaling are frequent in G3MB. Remarkably, some tumors have no reported mutations, suggesting roles for chromatin-driven mechanisms in this disease. We have generated novel humanized models for G3MB by transducing neuroepithelial stem cells (NESC) derived from human induced pluripotent stem cells with TGFβ effectors alone and/or in combination with MYC, prioritizing combinations observed in patients. We determined that both MYC and TGFβ effectors drove tumor formation in vivo with the combination driving more aggressive tumors and higher frequency of metastasis. Importantly, NESC-derived tumors clustered with human G3MB, indicating our models recapitulated human disease. To decipher mechanisms of resistance, we integrated CUT&RUN for MYC genomic localization and histone PTMs with RNA-sequencing and discovered MYC-bound neural developmental genes repressed in MYC and TGFβR1-driven lines. These gene signatures were associated with the Polycomb Repressive Complex (PRC) and demarcated with H3K27me3; the histone mark directly regulated by PRC. Further interrogation identified JARID1B, a MYC binding partner and H3K4me3 demethylase, as a regulator of these repressed neural genes. This is further reinforced by the observation of higher H3K27me3 levels concurrent with increased JARID1B expression in human G3MB patient samples, compared to other subtypes. We postulate that deregulation of MYC and context-specific targeting to the chromatin template culminates in transcriptional alterations that promote aggressive G3MB. These studies support a critical role of MYC in repressing target genes to drive tumor formation and JARID1B as a new target for therapy. Collectively, we present a critical framework for understanding mechanisms of resistance and the chromatin landscape of MYC- and TGFβ-driven G3MB.
Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
Fontana, Marianna , Grogan, Martha , Shah, Sanjiv J. , Engelmann, Mads D.M., Kristen, Arnt V. , Lim-Watson, Michelle , Malling, Brian , Kar, Soumitra , Revanna, Manjunatha, Sarswat, Nitasha , Maurer, Mathew S. , Garcia-Pavia, Pablo , Grogan, Martha , Shah, Sanjiv J , Lim-Watson, Michelle Z , Malling, Brian , Kar, Soumitra , Sarswat, Nitasha , Tsujita, Kenichi , Alexander, Kevin M , Maurer, Mathew S , Fontana, Marianna , Hovingh, G. Kees , Tsujita, Kenichi

Mayo Clinic

Circulation | November 10, 2025 | Volume: 153 | Issue: 4 | Pages: 214-225

10.1161/circulationaha.125.077304 | PMID 41212997 Get It

BACKGROUND: Transthyretin amyloidosis with cardiomyopathy is a progressive disease caused by the deposition of transthyretin (TTR) as amyloid in the myocardium. Current therapies may slow disease progression but do not clear existing deposits. Coramitug is a humanized monoclonal antibody that targets misfolded transthyretin, designed to promote clearance of transthyretin amyloid through antibody-mediated phagocytosis. METHODS: This phase 2, double-blind, placebo-controlled trial randomized participants with transthyretin amyloidosis with cardiomyopathy to receive infusions every 4 weeks of either coramitug at 2 dosages (10 mg/kg or 60 mg/kg) or placebo in a 1:1:1 ratio for 52 weeks. The primary end points were the change from baseline to week 52 in the 6-minute walk test and NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels. Safety was assessed for up to 64 weeks by assessing treatment-emergent adverse events, all-cause mortality, and number of cardiovascular events (comprising hospitalization caused by cardiovascular events or urgent heart failure visits). RESULTS: In total, 104 participants (median age, 77 years; 93% men; 84% New York Heart Association class II; 13% with variant transthyretin amyloidosis with cardiomyopathy) were randomized and dosed: 34 to 10 mg/kg of coramitug, 35 to 60 mg/kg of coramitug, and 35 to placebo. Median NT-proBNP was 1985 pg/mL (interquartile range, 1224, 3406). In total, 90% of participants were receiving disease-modifying therapy; 84% were treated with tafamidis and 7 (6.7%) with transthyretin silencers (patisiran, n=4; vutrisiran, n=3). From baseline to week 52, 60 mg/kg of coramitug significantly reduced NT-proBNP levels compared with placebo (–48% [95% CI, –65% to –22%]; P =0.0017). The change in 6-minute walk test from baseline to week 52 was not statistically different from placebo with either dose. Coramitug (60 mg/kg) was associated with improved functional echocardiographic parameters and was well tolerated. CONCLUSIONS: This phase 2 trial showed that coramitug, an antibody targeting misfolded transthyretin in transthyretin amyloidosis with cardiomyopathy, was well tolerated and, at a dose of 60 mg/kg, resulted in a statistically significant reduction in NT-proBNP, a validated marker of disease progression, with no statistically significant effect on 6-minute walk test within 52 weeks. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05442047.
Evaluation of Interventions for Cognitive Symptoms in Long COVID
Koltai, Deborah, Laskowitz, Daniel T. , Wisnivesky, Juan P., Federman, Alex D. , Silverstein, Adam M. , Lokhnygina, Yuliya, Haddad, Michelle M., Mahncke, Henry W. , Vleet, Tom Van, Huang, Rong , Cox, Wendy C., Terry, Diana, Karwowski, Jeannie, McCray, Netia, Lin, Jenny , Singh, Upinder , Geng, Linda N. , Reece, Rebecca , Moy, James N., Arvanitakis, Zoe , Parthasarathy, Sairam , Patterson, Thomas F., Gupta, Aditi , Parsonnet, Jeffrey, Kiriakopoulos, Elaine T. , Mullington, Janet , Jolley, Sarah E. , Shah, Nirav S. , Morimoto, Sarah Shizuko , Lee‐Iannotti, Joyce , Isache, Carmen, Frontera, Jennifer , O’Steen, Ashley, James, Melissa, Harper, Barrie, Zimmerman, Kanecia O. , Lawler, Andrew , Johnson, Brandon M. , Pitsch, Chloe E. , Feuerriegel, Elen , McKeehan, Jeffrey, Molden, Joie, Reid, Kayleigh M., Dowling, Sarah , Wodushek, Thomas, Canton, Diara, Turut, Dilara, Sheppard, Ethan , Scott‐Sutherland, Jennifer, Shaughnessy, Lynn, Beck, Michelle L. , Heisey, Sabrina, Katragadda, Vaishanvi, Yusuff, Amidat, Perlack, Amy, Merisme, Christie, Krause, David, Schulte, Duncan, Dupre, Fabiola, Sanchez, Gina A. Montealegre , Asupoto, Olanike, Simmons, Quinneil, Schroeder, Ryan W. , Timlin, Shannon, Devis, Ycar, Carter, Della, Caceres, Leomaris Caba, Rodríguez, Miguel Grande, Alvarez, Zariya , Yakubov, Amin , Engelson, Celia, Reyes, Michael, Youkhana, Alvin, Jennings, Cheryl , Naquiallah, Dina, Behun, Dylan , Stephen, Ellen, Timm, Emily , Bilimoria, Farrah, Li, Grace , Stricker, Thomas, Michelle, Kang, Minnie, Suarez, Rebeca Tojo, Carmona, Tania, Ramírez, Ana, Kadubek, Grace, Baker, Aileen, Romo-Serna, Andrea, Predki, Barbara, Leman, Cindy, Panhans, Cristina, Roth, Genevieve E., Rudraraju, Gowrisree , Miller, Hannah , DeLisa, Julie A., Williams, Kat, Woodson, Kimberly S., Jennette, Kyle J. , Villanueva, Laura, Norwick, Maria, Martínez, M. T., Rowley, Matt, Carrithers, Michael D. , Pliskin, Neil H. , Pérez, Nicolás , Durkin, Nicole M., Maniar, Nikita, Beety, Rachel, Daspgupta, Raktima, Ramchandran, Ramaswamy, Jaramillo, R., Hasek, Sharon, Macías, S Aguirre, Schuh, Tina , Ialacci, Sarah, Bailey, Christopher , Labbato, Danielle, Hautmann, Amanda , Smith, Beth, Nath, Dia, Meyer, Jessica , DiFrancesco, Kathryn, Pettinato, Kimberly, Curtis, Lynette, Daher, Joviane , Koberssy, Ziad , Mavar, Caleb, Andrefsky, John, Merheb, Alexander, Hernandez, Carla, Baissary, Jhony , Atieh, Ornina , Pereira, Carol, Carpenter, Deborah, Raynor, Jennifer , Brunton, Kristine, Podgoreanu, Andreea, Bunch, P. C., O’Brien, Sean M. , Dickey, Sheila, McNulty, Steven E., Gajjar, Varsha, Neale, Alec C. , Cohen, Cari, Geary, Elizabeth, Campanella, Franco, Anderson, Kirsten, Prestige, Laura, Guidotti-Breting, Leslie, Biewer, Megan, Morton, Melissa , Mathenia, Nicholas, Adeyemi, Oluwadamilola A. , Hengst, Samanike, Ning, Wei , Vanderloo, Adam, Caplan, Amanda, Chen, July, Acree, Mary Ellen , Nakhate, Mukund, Dan, Zaw Nu, Pk, Switzer, Aryal, Shambhu , Sanchez, Jessica, Sims, Luke, Ferdinand, Rebecca , Mammadova, Mehriban, Grimes, Carolyn Z. , Vidales, Elizabeth, Pham, Hau , Nielsen, Laura, Keller, Maryjane, Uruba, Syeda, Hernandez, Maria, Patel, Bela , Umana-Sanchez, Virginia, Pak, Chong, Gainer, Jeffery, BURR, R, Trapuzzano, Ashleigh, Celso, Brian G. , Bienkowski, Grace, Bowman, Jennifer, Verdecia, Jorge , Zerwekh, Kathryn, Serrano, Liliana , Marotz, Meghan, Propp, Piper, Sarig, Yonatan , Murphy, Annie, Comfort, Brandon, Torres, Iri, Klein, Jeffrey A. , Walker, John, Moore, John J., Tempest-Browning, Lisa, Arain, Mudassar, Kemp, Pamela, Sullivan, Samantha, Way, Sonja, Chevalier, Jessica, Sykes, Carly, Kruck, Carrie L., Sackett, L. W., Bang, Claire, Hynes, Mary, Gallagher, Torrey L., Childers-Kakos, Margaret, Zia, Ahmad, South, AP, Oravets, Anne, Ferreyra, Carolyn, Glaze, Chad, Villanueva, Daphne-Dominique , Blystone, Erica, Pritchard, Jane, Alyward, Laura, Cooper, Melissa, Chidester, Michelle, Alderson, R. Matt , Clark, Renee D., Hodder, Sally , Sarwari, Arif R, Juskowich, Joy, Welch, Shelly, Civil, Alyssa, Bendl, Ashley, Dicker, Elisa, Hanson, Hannah, Viola, Heather, Morinigo, Janice, Pantaleon, Karisma, Marcon, Kathryn, Stone, Kimberly, Stewart, Kiwan, Evo-Ortega, Lorraine, McVeety, Megan, Guliyeva, Sabina , Watson, Eric , Pehel, Shayna, Ko, Tim, Caropolo, Leah, Kocas, H. Deniz , O’Donnell, Andrew, Saperia, Corey , Thai, Daniel, Pathak, Divya , Keller, Jennifer M. , Olszewski, Kelly, Clinton, Kimberly, Cherian, Kirsten , Dutton, L M, Elepano, Ma, Mohapatra, Sukanya , Chen, Ting , Wroolie, Tonita, Leang, Zenita, Shashidhar, Sumana, Nguyen, T L, Ravisankar, Ashwath, Weiden, Brycie, Bolliger, Dawn, Glesne, Heather, Dixon, Jennifer , Chebrolu, Praneeth, Gazali, Zarine, Hurst, Whitney, Fry, Avery, Murthy, Ganesh, Grischo, Garrett, Erickson, Heidi L. , Gomez, Isaias, Copeland, Jacquelynn, Galaz, Judy, Autry, Lynn, DiLise-Russo, Marjorie, Marshell, Nikki, Borwege, Sabine, Vadovicky, Sheila, Marsh, Stephanie, Hartley, William, Murtagh, Linda, Kennedy, Anna, Meltzer-Christensen, Annie, Stringham, Caitlyn, Gaskin, Ella, Judd, Melissa, Côté, Sarah , Mahasenan, Shreya, Bjorklund, Todd, Farner, Cheryl E., Taylor, Barbara S. , Soileau, Bridgette, Cote, Cyrena , Hromas, Gabrielle A., Scholler, Irma, Longoria, Lisa, Heard, Patricia, Jones, Johnnie, Tragus, Robin , Harris, Maya, Pinones, Alexis, Anderson, Alyssa , Hastings, Gabrielyd, Courtright, jessica, Jayakumar, Madhumita, Fischer, M, Solis, Pamela, Harteloo, Alex, Elias-Warren, Anna, Nguyen, Daniel , McDonald, Dylan , Rau, Holly , Mernaugh, Jean, Pagulayan, Kathleen F. , Watanabe, Kino, Huden, Kristen, Peabody, Laurel, Mei, Tiffany, Ogunwuyi, Catherine, Cobbina, Esther, Sankar, Ian, Nguyen, Lisa , Fromm, N., Arnold, R. Douglas, Ogu, Stephanie, Yuan, Ying , Ibrahim, Homam , Szum, Izabella, Patel, Jignesh, Sultan, Sonia, Jazayeri, Yasmin, Anderson, Betty Lise, Muñoz, Isabel , Rhys, Logan, Vane, Ryan, Kim, Jessica , Diaz, Leticia M., Yee, Nathan, Gruhn, Robert, Browngoetz, Sarah, Johnson, Elisha, Chand, Arista , Bottrill, Kenneth , Henderson, Kymberly, Johnson, DeArmond, Richard C., Hughes, Trina, Silverstein, A , Silverstein, Adam P , Frontera, Jennifer , Geng, Linda N. , Knopman, David S. , Becker, Jacqueline , Charvet, Leigh , Pilloni, Giuseppina , Huang, Rong, Cox, Wendy, Karwowski, Jeannie, McComsey, Grace A. , Chu, Helen Y. , Ostrosky‐Zeichner, Luis , Fong, Tamara G. , Killgore, William D. S. , Dwyer, Brigid C. , Stringer, William W. , Krishnan, Jerry A , James, Melissa, Johnson, Brandon, Erlandson, Kristine M. , Dowling, Sarah, Hauser, Kristine , Doyle, Michael, Beck, Michelle, Tran, Anh, Altaras, Caroline , Sanchez, Gina, Krengel, Maxine , Ly, Monica T. , Asupoto, Olanike, Schroeder, Ryan, Rodriguez, Miguel, González, David Andrés , Torres, Jimena, García, Maria Luisa , Carrera, Laura, Rutherford, Melissa, Perez, Nicolas, Jaramillo, Ruthie, Smith, Beth, Walkup, Kevin, Scott, Sarah , Mavar, Caleb B., Carpenter, Deborah, Bunch, Pyper, Brown, Richard, Escobar, Carolina, Campanella, Franco, Mathenia, Nicholas, Glickman, Michael S. , Sims, Luke A., Pham, Hoai Phuang, Lopez, John, Hernandez, Maria, Lin, Matthew Junda , Gainer, Jeffery, Brown, Gina , Klein, Jeffrey, Reed, Jessica, Walker, John, Sackett, Lisa, Kaden, Sarah J. , Childers-Kakos, Margaret G, South, Amy, Blystone, Erica, Cooper, Melissa, Alderson, Rachael, Clark, Renee, Bardes, James M. , Hanson, Hannah, Loizos, Maria , Caropolo, Leah J., Fernandez, Luis, Keller, Jennifer, Lin, Rebecca, Brown, Daniel, Dixon, Jennifer, James, Michelle, Kala, Mrinalini , Smith, Ryan S. , Mahasenan, Shreya, Johnson, Hillary, Anderson, Alyssa, Hernandez, Jessica, Sullivan, Michael, Nguyen, Helen , Logue, Jennifer, Mei, Tiffany, Arnold, Rowan, Szum, Izabella , Hatlen, Timothy J. , Anderson, Betty, Munoz, Isabel, Wright, Matthew, Diaz, Leticia, DeCato, Thomas W. , Ortiz, Ernesto, Hildebrand, Lindsey L. , DeArmond, Richard

Mayo Clinic

JAMA Neurology | November 10, 2025 | Volume: 83 | Issue: 1 | Pages: 49

10.1001/jamaneurol.2025.4415 | PMID 41212544 Get It

Importance Treatment for cognitive dysfunction due to postacute sequelae of long COVID (ie, symptoms of fatigue, malaise, weakness, confusion that persist beyond 12 weeks after an initial COVID infection) remains a significant unmet need. Objective To test evidence-based rehabilitation strategies for improving cognitive symptoms in persons with long COVID. Design, Setting, and Participants This was a 5-arm, multicenter, randomized clinical trial of 3 remotely delivered interventions conducted between August 17, 2023, and June 10, 2024. The study took place at 22 trial sites and included the screening of individuals with cognitive long COVID. Interventions Participants were randomized to 1 of 5 arms: adaptive computerized cognitive training (BrainHQ [Posit Science]), cognitive-behavioral rehabilitation involving both group and individual counseling sessions (PASC-Cognitive Recovery [PASC-CoRE]) paired with BrainHQ, and transcranial direct current stimulation (tDCS) paired with BrainHQ. Two comparator arms were included as follows: unstructured computer puzzles and games (active comparator) and sham tDCS paired with BrainHQ. The interventions occurred 5 times per week over 10 weeks. Main Outcomes and Measures Cognitive and behavioral in-person assessments were performed at baseline, midintervention, at the end of intervention, and 3 months after the end of the intervention. The primary outcome measure was the modified Everyday Cognition Scale 2 (ECog2) completed at the end of the intervention compared to the baseline visit based on participant self-report looking back over the prior 7 days. Results A total of 378 individuals were screened, from which there were 328 participants (median [IQR] age, 48.0 [37.0-58.0] years; 241 female [73.5%]; race: 15 Asian [4.6%], 47 Black [14.3%], and 235 White [71.6%]; ethnicity: 52 Hispanic [15.9%]). None of the 3 active interventions demonstrated benefits on the modified ECog2 in the intention-to-treat population by the end of the intervention period. The adjusted differences in mean change were 0.0 (95% CI, −0.2 to 0.2) for BrainHQ vs active comparator, 0.1 (95% CI, −0.1 to 0.3) for PASC-CoRE + BrainHQ vs active comparator, 0.0 (95% CI, −0.2 to 0.2) for tDCS-active + BrainHQ vs tDCS-sham + BrainHQ, and 0.1 (95% CI, −0.1 to 0.3) for PASC-CoRE + BrainHQ vs BrainHQ alone. Secondary participant-reported outcomes and neuropsychological tests showed no differential benefits for any treatment arm. All 5 arms demonstrated some improvements over time on the modified ECog2 and on secondary outcomes. There were no serious adverse events attributable to the interventions. Conclusions and Relevance This phase 2 randomized clinical trial failed to demonstrate differential benefits for online cognitive training, a structured cognitive rehabilitation program, and tDCS for cognitive long COVID. Trial Registration ClinicalTrials.gov Identifier: NCT05965739 .